Why you soon won't be able to find Incannex shares on the ASX

This healthcare share plans to pack its bags and move to the US.

| More on:
Man sitting in a plane seat works on his laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The days of Incannex Healthcare Ltd (ASX: IHL) shares trading on the ASX boards are now numbered.

That's because this morning, the cannabis-focused clinical-stage pharmaceutical development company has announced plans to redomicile from Australia to the United States.

This will be via proposed schemes of arrangement between Incannex and its shareholders and option holders, subject to their approval, as well as customary regulatory approvals.

Why are Incannex shares leaving the ASX?

According to the release, the Incannex board believes that becoming a U.S. company and trading only on the NASDAQ will provide many and varied benefits to Incannex and its shareholders.

It believes that the company will have greater access to a more cognisant and receptive capital market of Incannex's value proposition. The board also highlights that comparison companies are trading at far greater market valuations and switching would provide it with the ability to expand to a much broader investor base.

Incannex CEO and Managing Director, Joel Latham, said:

The Board is excited to enact this landmark unanimous decision in conjunction with our key shareholders and other stakeholders. It is a decision made with the intention to maximise shareholder value.

Incannex has matured on the ASX to the point that it has a large and diversified drug portfolio with two exciting drug candidates imminently entering pivotal clinical trials. By committing our presence to the United States, we believe that our Company's visibility to international investors will increase markedly, partly due to our value proposition compared to similar emerging biotech companies with a presence in North America.

What's next?

The company expects to allow shareholders to vote on the proposal at a meeting in October.

If the proposal is approved, holders of Incannex shares will be entitled to receive one share of common stock in Incannex US for every 100 shares held on the record date for the share scheme. The value of the holding would remain the same at conversion.

Incannex shares are down 40% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »